Table 2.
Results of univariate analyses carried out to identify prognostic factors in patients with resected non-small cell lung cancer
| Training set (n = 47) | Test set (n = 100) | |||
|---|---|---|---|---|
| Hazard ratio | P | Hazard ratio | P | |
| APA score ≥5 | 3.9 | 0.009 | 5.4 | <0.001 |
| Age ≥70 years | 1.1 | NS | 0.6 | NS |
| Male | 3.5 | NS | 1.7 | NS |
| Positive smoking history | 2.6 | NS | 2.3 | NS |
| Non-adenocarcinoma | 3.1 | 0.03 | 2.8 | 0.02 |
| T2, T3 | 13.7 | <0.001 | 5.2 | <0.001 |
| N1, N2 | 2.9 | 0.04 | 9.7 | <0.001 |
| Lymphatic invasion (+) | 3.3 | 0.02 | 5.8 | <0.001 |
| Vascular invasion (+) | 1.9 | NS | 8.2 | <0.001 |
| Adjuvant chemotherapy | 2.5 | NS | 4.8 | <0.001 |
| Loss of PABPN1† | 3.7 | 0.02 | 5.3 | <0.001 |
| Loss of CPEB1† | 0.7 | NS | 3.4 | 0.003 |
| Gain of MKI67† | 1.5 | NS | 4.2 | <0.001 |
| Gain of TOP2A† | 1.5 | NS | 5.3 | <0.001 |
| Gain of MCM2† | 2.9 | NS | 2.2 | 0.04 |
| Gain of E2F1† | 1.0 | NS | 2.9 | 0.008 |
†
The median expression value of each gene was used as the threshold to divide the patients into two groups: those with either loss or gain of expression. APA, alternative polyadenylation; NS, not significant.